Stockscreener 앱 받기
10.59
0.00%
0.00
시간 외 거래:
10.95
0.36
+3.40%
Cullinan Therapeutics Inc 주식(CGEM)의 최신 뉴스
Why Cullinan Therapeutics Inc. stock could benefit from AI revolution2025 Volatility Report & Weekly Hot Stock Watchlists - Newser
How Cullinan Therapeutics Inc. stock benefits from strong dollarJuly 2025 EndofMonth & High Conviction Buy Zone Picks - Newser
Cullinan Therapeutics (NASDAQ:CGEM) Shares Down 7.3%What's Next? - MarketBeat
There is no doubt that Cullinan Therapeutics Inc (CGEM) ticks all the boxes. - Setenews
How Cullinan Therapeutics Inc. stock responds to policy changesEarnings Risk Summary & Free Weekly Watchlist of Top Performers - Newser
FDA grants fast track designation to Cullinan’s AML therapy By Investing.com - Investing.com Australia
Cullinan Oncology stock rises after FDA Fast Track designation for leukemia drug - Investing.com Canada
Cullinan Therapeutics receives FDA fast track designation for CLN-049 - marketscreener.com
CGEM Receives FDA Fast Track for CLN-049 in Leukemia Treatment - GuruFocus
Cullinan Therapeutics' CLN-049 Receives FDA Fast Track Designation for Treatment of Relapsed/Refractory Acute Myeloid Leukemia - Quiver Quantitative
FDA grants fast track designation to Cullinan’s AML therapy - Investing.com
Cullinan Therapeutics Receives FDA Fast Track Designation - GlobeNewswire
Insider Selling: Cullinan Therapeutics (NASDAQ:CGEM) Insider Sells 4,000 Shares of Stock - MarketBeat
Cullinan Therapeutics (NASDAQ:CGEM) Trading Down 7.6%Should You Sell? - MarketBeat
Cullinan Oncology stock price target raised to $36 at Jones Trading - Investing.com Nigeria
Why Cullinan Therapeutics (CGEM) Is Up 38.1% After FDA Filing for EGFR-mutant Lung Cancer Drug - Sahm
Buy Rating for Cullinan Therapeutics Driven by Promising AML Treatment Developments and Strong Market Potential - TipRanks
Foresite Capital Management VI LLC Lowers Stock Position in Cullinan Therapeutics, Inc. $CGEM - MarketBeat
Taiho Oncology and Cullinan Therapeutics Announce Acceptance of Abstracts for Zipalertinib at the IASLC 2025 World Conference on Lung Cancer (PR Newswire) - Aktiellt
Cullinan Therapeutics (NASDAQ:CGEM) Sees Large Volume IncreaseShould You Buy? - MarketBeat
Investors Purchase High Volume of Call Options on Cullinan Therapeutics (NASDAQ:CGEM) - MarketBeat
Is Cullinan Therapeutics Inc (CGEM) positioned for future growth? - Setenews
Cullinan Oncology stock price target raised to $38 at BTIG on promising AML data - Investing.com Canada
Taiho, Cullinan file rolling NDA on phase I/II zipalertinib data - BioWorld MedTech
BTIG Maintains Cullinan Therapeutics (CGEM) Buy Recommendation - Nasdaq
Cullinan Therapeutics (CGEM) Receives PT Upgrade from BTIG Analy - GuruFocus
Cullinan Therapeutics price target raised to $38 from $32 at BTIG - TipRanks
Why LexinFintech Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Cullinan Management Ends Development of CLN-617 - MSN
Cullinan Therapeutics (NASDAQ:CGEM) Price Target Raised to $26.00 - Defense World
Wall Street Zen Upgrades Cullinan Therapeutics (NASDAQ:CGEM) to Hold - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Upgraded by Wall Street Zen to Hold Rating - MarketBeat
Wedbush Reiterates “Outperform” Rating for Cullinan Therapeutics (NASDAQ:CGEM) - Defense World
Cullinan Therapeutics' (CGEM) "Outperform" Rating Reaffirmed at Wedbush - MarketBeat
Cullinan TherapeuticsCullinan Amber notified MIT decision to terminate exclusive patent license agreement for CLN-617 - marketscreener.com
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Up 8.5% Following Analyst Upgrade - Defense World
Cullinan Therapeutics (NASDAQ:CGEM) Stock Price Up 8.5% After Analyst Upgrade - MarketBeat
HC Wainwright Forecasts Strong Price Appreciation for Cullinan Therapeutics (NASDAQ:CGEM) Stock - MarketBeat
Otsuka units file for US approval for zipalertinib - The Pharma Letter
Cullinan Therapeutics (CGEM) Advances with FDA Acceptance for Lu - GuruFocus
Cullinan Therapeutics rises on rolling submission for zipalertinib - MSN
HC Wainwright & Co. Maintains Cullinan Therapeutics (CGEM) Buy Recommendation - Nasdaq
HC Wainwright & Co. Raises Price Target for CGEM to $26.00 | CGE - GuruFocus
CGEM Advances NDA for Zipalertinib Targeting EGFR Mutations in N - GuruFocus
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics initiate rolling submission of new drug application to US FDA - MarketScreener
Taiho Oncology, Taiho Pharmaceutical and Cullinan Therapeutics Initiate Rolling Submission of New Drug Application for Zipalertinib for Treatment of Locally Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations - marketscreener.com
Can Cullinan Therapeutics Inc. stock beat market expectations this quarterGDP Growth & Safe Capital Growth Plans - newser.com
Heatmap analysis for Cullinan Therapeutics Inc. and competitors2025 Investor Takeaways & Expert Approved Momentum Ideas - newser.com
Visual analytics tools that track Cullinan Therapeutics Inc. performance2025 Pullback Review & Free Verified High Yield Trade Plans - newser.com
How Cullinan Therapeutics Inc. stock trades during market volatilityJuly 2025 Summary & Proven Capital Preservation Tips - newser.com
Is Cullinan Therapeutics Inc. reversing from oversold territoryFed Meeting & Fast Gain Stock Trading Tips - newser.com
Will Cullinan Therapeutics Inc. rebound enough to break evenInsider Buying & Verified Entry Point Detection - newser.com
Will Cullinan Therapeutics Inc. stock maintain dividend yieldPortfolio Update Report & High Yield Stock Recommendations - newser.com
Cullinan Therapeutics Inc. stock outlook for YEARIndex Update & Reliable Price Breakout Alerts - newser.com
Using data filters to optimize entry into Cullinan Therapeutics Inc.July 2025 News Drivers & High Conviction Buy Zone Picks - newser.com
Backtesting results for Cullinan Therapeutics Inc. trading strategiesJuly 2025 Big Picture & Real-Time Chart Breakout Alerts - newser.com
Cullinan Therapeutics Inc. stock daily chart insightsWeekly Stock Summary & Weekly High Potential Alerts - newser.com
What makes Cullinan Therapeutics Inc. stock attractive to growth fundsJuly 2025 Trade Ideas & Fast Moving Stock Trade Plans - newser.com
1.44%
0.91%
자본화:
|
볼륨(24시간):